NCT03594890 - Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

August 7, 2019

Study Completion Date

August 7, 2019

Conditions

Influenza

Interventions

BIOLOGICAL

OVX836 (Intramuscular)

2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.

BIOLOGICAL

Placebo (Intramuscular)

2 consecutive administrations of placebo at Day 1 and Day 29.

BIOLOGICAL

OVX836 (Intranasal)

2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.

BIOLOGICAL

Placebo (Intranasal)

2 consecutive administrations of placebo at Day 1 and Day 29.

Trial Locations (1)

Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp